Clinical utility of [^18F]FDG PET/CT in the assessment of mediastinal lymph node disease after neoadjuvant chemoimmunotherapy for non-small cell lung cancer

[1]  Y. She,et al.  Lung cancer with PET/CT-defined occult nodal metastasis yields favourable prognosis and benefits from adjuvant therapy: a multicentre study , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  J Zhang,et al.  Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer. , 2022, Lung cancer.

[3]  N. Ajami,et al.  Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer , 2021, Nature Communications.

[4]  D. Lin,et al.  Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer , 2021, Modern Pathology.

[5]  Jinming Yu,et al.  PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy. , 2021, Cancer letters.

[6]  I. Wistuba,et al.  Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy. , 2021, Journal of Thoracic Oncology.

[7]  C. Belka,et al.  PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  N. Ajami,et al.  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial , 2021, Nature Medicine.

[9]  J. Wolchok,et al.  CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors , 2021, Nature.

[10]  Shanshan Jiang,et al.  The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer , 2021, Cancer Immunology, Immunotherapy.

[11]  W. Liang,et al.  Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer , 2020, Translational lung cancer research.

[12]  R. Rami-Porta,et al.  Complete Resection in Lung Cancer Surgery: From Definition to Validation and Beyond. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  W. Schreurs,et al.  Surveillance of Clinically Complete Responders Using Serial 18F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy , 2020, The Journal of Nuclear Medicine.

[14]  S. Mandrekar,et al.  Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  J. Rathmell,et al.  Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. , 2020, Molecular cell.

[16]  Ning Li,et al.  The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Prasad Adusumilli,et al.  IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  D. Gandara,et al.  IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  G. Antoch,et al.  Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  G. Turgeon,et al.  What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non–Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria? , 2018, The Journal of Nuclear Medicine.

[21]  David R. Jones,et al.  Management of stage IIIA (N2) non-small-cell lung cancer: a transatlantic perspective†. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[22]  David R. Jones,et al.  Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. , 2016, The Journal of thoracic and cardiovascular surgery.

[23]  E. Gontier,et al.  18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer , 2015, The Journal of Nuclear Medicine.

[24]  C. Dooms,et al.  Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[25]  J. Hatazawa,et al.  Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study , 2011, Annals of nuclear medicine.

[26]  M Oudkerk,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  G. Jiang,et al.  Single-port video-assisted thoracic surgery in 1063 cases: a single-institution experience†. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.